GenProbe (GPRO) up 8%+on Buy-Out Rumors
Speculation chat is driving up shares of GenProbe (GPRO) on heavier volume of 2.5M shares. Two stories are notable one from the Wall Street Journal on ThermoFisher (TMO) a potential bidder, but also interested in Phadia AB an allergy testing Co., and the other on a collaboration between...
Metrics of Pure Play Diagnostic Companies: Comparison to GenProbe
M&A Premium of Diagnostic Companies Bloomberg reported on April 29 that GenProbe (GPRO) was seeking a buyer. We reported earlier this month on the M&A trend in biotechnology, tools and diagnostics and we will begin following the sector looking for value and potential buy-out targets....
Big Sell-Off in Oil, Gas and Other Commodities Spooks the Market
Relative Safety in Healthcare Stocks Today's sell-off in the energy complex with the back-drop of a U.S. slow growth scenario plus the Euro being vulnerable due to Greece and Ireland has spooked the overall market. All the major indices are down over 1% with the S&P down 1.22%. Nasdaq is...
Life Science Stocks Capture M&A Premium
Deals Are Bullish for the Market Yesterday's Alkermes (ALKS) deal with Elan (ELN) supports the major M&A trend in the life science market. Timing is everything in a hot market. The rationale for the current M&A activity is: technologies and pipeline fit strategically, money is cheap,...
Life Science Stocks Are Deal Driven: Alkermes (ALKS) and Elan(ELN) Merge Technologies
Good Technology Fit Helped By Cheap Money and Tax Benefits M&A has been one of the main drivers of the biotech market and today we have more recombinant action as Alkermes (ALKS) of Boston is buying the EDT drug delivery unit of Elan (ELN) of Ireland for $960M. Elan would receive $500M in...